Column: Trump's address to Congress trumpets how he usurps Congress

President Trump used the State of the Union to claim credit for accomplishments while asserting unilateral authority on trade and policy, even after the Supreme Court in a 6-3 decision struck down his use of unilateral tariffs. Justice Gorsuch’s concurrence urged Congress to reclaim its constitutional lawmaking role, highlighting institutional friction as the administration signals it may pursue alternative legal paths to continue tariff measures. For investors, this underscores continued policy and legal uncertainty—tariff risk remains salient despite the court ruling, and midterm election outcomes could materially change the legislative balance that determines the durability of any major economic policies.

Analysis

Market structure: The immediate consequence is increased policy uncertainty rather than an outright regime shift — winners in a tariff/edge-control scenario would be domestic materials (steel: NUE, X) and defense contractors (LMT, GD, RTX) while import‑dependent retail and consumer names (TGT, M, AMZN exposure to global supply chains) face margin pressure. The Supreme Court rebuke reduces the probability of large, sustained unilateral tariffs in the next 3–6 months but preserves episodic legal/regulatory skirmishes that raise idiosyncratic volatility for affected sectors.

Risk assessment: Tail risks include an escalatory trade response (formal tariffs or retaliatory measures) and midterm-driven policy swings that could widen equity–bond dispersion; low‑probability shocks (a rapid tariff implementation via alternate statutes) would be high impact for supply chains and inflation. Time buckets: immediate (days) = headline volatility; short (weeks–months) = litigation and executive orders; long (quarters) = legislative changes after midterms; monitor SCOTUS/DoJ memos and House Judiciary calendar for triggers.

Trade implications: Tactical plays are long defense and domestic steel for 3–12 months and short import‑sensitive retail over the same horizon; use options to cap downside — e.g., buy 3‑6 month puts on TGT and buy 3‑6 month calls on LMT as asymmetric exposure. Credit and FX: dollar strength on risk-off and treasury duration bids (TLT) are reliable hedges; commodities like copper/soy will react to trade rhetoric but need on‑the‑ground tariff specifics to move materially.

Contrarian angles: Consensus overstates immediate tariff permanence — courts and Congress still constrain policy, so volatility is tradeable, not structural. The market underprices regulatory execution risk on drug pricing (MFN moves) and overprices uniform impact across all retailers; targeted names with concentrated China exposure will suffer most. Historical parallel: 2018 tariff episode — 6–12 months of dispersion then reversion once legal/negotiation pathways clarified.

Key Decisions for Investors

• Establish a 2–3% long position split evenly across LMT, GD and RTX (0.7–1.0% each) over a 3–12 month horizon to capture potential defense/border‑security spending; set a hard stop at -12% and trim 50% on a 20% relative outperformance vs. SPY.
• Implement a 2% pair trade (1% long NUE, 1% short TGT) for 3–6 months to play tariff upside for steel vs. retail margin pressure; unwind if legislation or court rulings within 90 days remove tariff pathways or if NUE/TGT relative moves exceed 15%.
• Buy a protective SPY put spread sized to 1% of portfolio (buy 3‑month 5% OTM puts, sell 3‑month 10% OTM puts) as a cost‑effective hedge against headline risk over the next 90 days; exit after volatility reverts below VIX=15 or 30 days post‑midterms.
• Establish a conditional 1–2% downside position in large pharma (buy 6‑month PFE 10% OTM puts) that triggers if an MFN or similar drug‑pricing proposal is publicly filed or leaked within 60 days, cap exposure at 2% and re-evaluate after policy text is released.